FibroGen Community

NasdaqGS:FGEN Community

1 Narratives written by author
0 Comments on narratives written by author
1 Fair Values set on narratives written by author

AN

AnalystConsensusTarget

Consensus Narrative from 1 Analyst

Simplifying Operations And Advancing FG-3246 Will Secure Future Success

Key Takeaways Strategic cost reductions and the sale of FibroGen China enhance financial stability, extending cash runway and potentially boosting overall financial performance. Focus on high-value oncology, including FG-3246 and roxadustat, positions the company for future revenue growth and increased market opportunities.

US$10.00

FV

97.1% undervalued

60.01%

Revenue growth p.a.

0

0

1

5 days ago